Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity

Study Objective. To evaluate the metabolism of antipyrine, a general metabolic probe, caffeine, a probe for cytochrome P450 (CYP) 1A2 and N‐acetyltransferase activity, and dextromethorphan, a specific probe for CYP2D6 activity in patients with type 1 or 2 diabetes mellitus.

[1]  P. Bechtel,et al.  The influence of insulin‐dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[2]  J. Schenkman,et al.  Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. , 1990, Molecular pharmacology.

[3]  C. Ioannides,et al.  Induction of hepatic microsomal P450 I and IIB proteins by hyperketonaemia. , 1990, Biochemical pharmacology.

[4]  R. Straka,et al.  Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota , 1995, Clinical pharmacology and therapeutics.

[5]  M. Danhof,et al.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. , 1979, Pharmacology.

[6]  C. Shashindran,et al.  ANTIPY RINE METABOLISM IN PATIENTS WITH DIABETES MELLITUS , 1983 .

[7]  R. Straka,et al.  Determination of Dextromethorphan and Its O-Demethylated Metabolite from Urine , 1992, Therapeutic drug monitoring.

[8]  W. Schweisheimer.  [DIABETES IN ANIMALS]. , 1964, Medizinische Klinik.

[9]  C. Ioannides,et al.  Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. , 1990, The Biochemical journal.

[10]  P. Sretarugsa,et al.  Comparative effects of diabetogenic agents on hepatic drug metabolism. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[11]  P. Gwilt,et al.  The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans , 1991, Clinical pharmacokinetics.

[12]  U. Fuhr,et al.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. , 1994, Pharmacogenetics.

[13]  C. Adithan,et al.  Differential effect of type I and type II diabetes mellitus on antipyrine elimination. , 1989, Methods and findings in experimental and clinical pharmacology.

[14]  B. Tang,et al.  The use of caffeine for enzyme assays: A critical appraisal , 1993, Clinical pharmacology and therapeutics.

[15]  H. Kroemer,et al.  Use of Probe Drugs as Predictors of Drug Metabolism in Humans , 1997, Journal of clinical pharmacology.

[16]  R. Kato,et al.  Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. , 1989, Archives of biochemistry and biophysics.

[17]  B. Tang,et al.  Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping , 1991, Clinical pharmacology and therapeutics.

[18]  C. Ioannides,et al.  Streptozotocin-induced diabetes modulates the metabolic activation of chemical carcinogens. , 1988, Chemico-biological interactions.

[19]  C. Adithan,et al.  Effect of type II diabetes mellitus on theophylline elimination. , 1988, International journal of clinical pharmacology, therapy, and toxicology.

[20]  B. Rodrigues,et al.  Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. , 1988, Molecular pharmacology.

[21]  P. Saenger,et al.  Hepatic drug metabolism is increased in poorly controlled insulin-dependent diabetes mellitus. , 1990 .

[22]  P. Salmela,et al.  The Evaluation of the Drug-metabolizing Capacity in Patients with Diabetes Mellitus , 1980, Diabetes.

[23]  U. Hofmann,et al.  Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.

[24]  O. Pelkonen,et al.  Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  R. Branch,et al.  A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma : Application to CYP1A2 phenotyping , 1998 .

[26]  J. Schenkman.  Induction of diabetes and evaluation of diabetic state on P450 expression. , 1991, Methods in enzymology.

[27]  L. D. de Leede,et al.  Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state. , 1985, The Journal of pharmacology and experimental therapeutics.

[28]  G. Shenfield,et al.  The effect of glucose on acetylation status. , 1986, British journal of clinical pharmacology.

[29]  K. O'malley,et al.  Influence of diabetes mellitus on drug metabolism in man. , 1976, International journal of clinical pharmacology and biopharmacy.

[30]  P. Salmela,et al.  Liver Function Tests in Diabetic Patients , 1984, Diabetes Care.

[31]  S. Loft,et al.  Antipyrine as a model drug to study hepatic drug-metabolizing capacity. , 1988, Journal of hepatology.

[32]  L. Silbart,et al.  Human N‐acetylation genotype determination with urinary caffeine metabolites , 1990, Clinical pharmacology and therapeutics.

[33]  C. Ioannides,et al.  Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. , 1992, Biochemical pharmacology.

[34]  D. A. Staats,et al.  Changes in hepatic drug metabolism in alloxan-diabetic male rabbits. , 1986, Biochemical pharmacology.